Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors

被引:26
作者
Haghshenas, M. R. [1 ]
Khademi, B. [1 ,2 ]
Ashraf, M. J. [3 ]
Ghaderi, A. [1 ]
Erfani, N. [1 ]
机构
[1] Shiraz Univ Med Sci, Sch Med, Shiraz Inst Canc Res, Canc Immunol Grp, Shiraz, Iran
[2] Shiraz Univ Med Sci, Khalili Hosp, Dept Otolaryngol, Shiraz, Iran
[3] Shiraz Univ Med Sci, Khalili Hosp, Dept Pathol, Shiraz, Iran
关键词
Th1; Th2; Tc1; Tc2 and salivary gland tumors; DENDRITIC CELLS; TYPE-1; LYMPHOCYTES; IL-4; IMMUNOTHERAPY; EXPRESSION; IMBALANCE; CARCINOMA;
D O I
10.1111/odi.12496
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
ObjectiveThe objective of this study was to explore the prevalence of T helper type 1 (Th1; CD4(+)IFN-(+)) and Th2 (CD4(+)IL-4(+)) cells, as well as cytotoxic T cell type 1 (Tc1; CD8(+)IFN-(+)) and Tc2 cells (CD8(+)IL-4(+)) in peripheral blood of the patients with salivary gland tumors (SGTs). Subjects and Methods: Thirty new patients with SGTs and 15 healthy controls were recruited. After intracellular cytokine staining, data acquisition and analysis were performed by flow cytometry. ResultsThe mean percentages of Th1 and Tc1 cells, as well as the ratios of Th1/Th2 and Tc1/Tc2, were observed to be significantly lower in patients with malignant SGTs in comparison with controls. Furthermore, the geometric mean fluorescent intensity (geometric MFI, representing the cytokine expression intensity) for IL-4 production by Th2 and Tc2 lymphocytes was significantly higher in patients with malignant tumors than controls. Positive correlations were observed between the mean percentage of Tc2 cells with Th2 cells, and with the tumor size in patients with benign and malignant tumors, respectively. ConclusionThe findings suggest that the imbalance of Th1/Th2 and Tc1/Tc2 ratios, as well as the increase in the expression of IL-4 by Th2 and Tc2 lymphocytes, may contribute to the pathogenesis of SGTs, especially in malignant cases.
引用
收藏
页码:566 / 572
页数:7
相关论文
共 27 条
[1]   The 3 major types of innate and adaptive cell-mediated effector immunity [J].
Annunziato, Francesco ;
Romagnani, Chiara ;
Romagnani, Sergio .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (03) :626-635
[2]   Management and outcome of patients with malignant salivary gland tumors [J].
Bell, RB ;
Dierks, EJ ;
Homer, L ;
Potter, BE .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 63 (07) :917-928
[3]   The tumor enhancement phenomenon: Reinterpretation from a Th1/Th2 perspective [J].
Clerici, M ;
Clerici, E ;
Shearer, GM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (07) :461-462
[4]   Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses [J].
Dobrzanski, MJ ;
Reome, JB ;
Hollenbaugh, JA ;
Dutton, RW .
JOURNAL OF IMMUNOLOGY, 2004, 172 (03) :1380-1390
[5]   Immune profiles of CD4+lymphocyte subsets in breast cancer tumor draining lymph nodes [J].
Faghih, Zahra ;
Erfani, Nasrollah ;
Haghshenas, Mohammad Reza ;
Safaei, Akbar ;
Talei, Abdol-Rasoul ;
Ghaderi, Abbas .
IMMUNOLOGY LETTERS, 2014, 158 (1-2) :57-65
[6]  
Goyal G, 2015, ONCOLOGY-NY, V29, P773
[7]   Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors [J].
Haghshenas, Mohammad Reza ;
Khademi, Bijan ;
Faghih, Zahra ;
Ghaderi, Abbas ;
Erfani, Nasrollah .
IMMUNOLOGY LETTERS, 2015, 164 (02) :109-116
[8]   Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses [J].
Iezzi, Giandomenica ;
Boni, Andrea ;
Degl'Innocenti, Elena ;
Grioni, Matteo ;
Bertilaccio, Maria T. S. ;
Bellone, Matteo .
JOURNAL OF IMMUNOLOGY, 2006, 177 (04) :2131-2137
[9]  
Ito N, 1999, CANCER, V85, P2359, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2359::AID-CNCR10>3.0.CO
[10]  
2-A